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The precise definition of the post-operative resection status in high-grade gliomas (HGG) is
crucial for further management. We aimed to assess the feasibility of assessment of the
resection status with early post-operative positron emission tomography (PET) using [18F]
O-(2-[18F]-fluoroethyl)-L-tyrosine ([18F]FET).
Methods
25 patients with the suspicion of primary HGG were enrolled. All patients underwent pre-
operative [18F]FET-PET and magnetic resonance imaging (MRI). Intra-operatively, resec-
tion status was assessed using 5-aminolevulinic acid (5-ALA). Imaging was repeated within
72h after neurosurgery. Post-operative [18F]FET-PET was compared with MRI, intra-opera-
tive assessment and clinical follow-up.
Results
[18F]FET-PET, MRI and intra-operative assessment consistently revealed complete resec-
tion in 12/25 (48%) patients and incomplete resection in 6/25 cases (24%). In 7 patients,
PET revealed discordant findings. One patient was re-resected. 3/7 experienced tumor
recurrence, 3/7 died shortly after brain surgery.
Conclusion
Early assessment of the resection status in HGG with [18F]FET-PET seems to be feasible.
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Introduction
The importance of complete resection of contrast-enhancing tumor in patients with malignant
gliomas has been highlighted by several studies [1, 2]. The precise definition of the early post-
operative resection status in high-grade gliomas (HGG) is crucial for further treatment plan-
ning, e.g. delineation of the radiation field in radiotherapy or surgical re-evaluation if larger
residual tumor is present.
Magnetic resonance imaging (MRI) represents the state-of-the-art technique for brain
tumor imaging. T1- and T2-weighted sequences provide information on glioma size and locali-
zation as well as additional insights on secondary phenomena, i.e. edema, bleeding, necrosis
and signs of increased intracranial pressure [3, 4]. In the early postoperative setting after brain
tumor surgery, MRI is the imaging modality of choice to verify the resection status. However,
the time window for imaging is restricted, because reactive tissue changes normally start to
evolve after 48–72 hours.
Many studies have demonstrated the value of [18F]O-(2-[18F]-fluoroethyl)-L-tyrosine posi-
tron emission tomography ([18F]FET-PET) for delineation of tumor tissue [5–8] and definition
of the optimal biopsy site whereas MRI changes may be unspecific and exceed true tumor
boundaries (3–5). Additionally, malignant high-grade gliomas can present without contrast
enhancement and may thereby be underestimated by MRI [5, 8–10]. In contrast, amino acid
tracer uptake even in non-solid, infiltrative parts of gliomas has been demonstrated [11, 12].
Moreover, [18F]FET-PET offers a superior differentiation between tumor tissue and reactive
changes as it does not accumulate in inflammatory or reactive processes [13, 14]. It improves
tumor recurrence detection and results in a better definition of target volumes prior to radia-
tion therapy [15–17].
In this study we investigated the value of early post-operative [18F]FET-PET to assess the
resection status in comparison to intra-operative findings as well as MRI.
Patients and Methods
Patients
Twenty five consecutive patients (16 males, 9 females; mean age, 62±14 y [range, 26–78 years])
with suspected primary HGG were prospectively enrolled in this study. Tumor surgery was
performed in all subjects using dedicated neuro-navigation software (iPlan 3.0; BrainLab, Feld-
kirchen; Germany), in eloquent localizations with intraoperative neuromonitoring by somato-
sensory evoked potentials (SSEP) and motor evoked potentials (MEP). Tumor tissue was
removed using the cavitron ultrasonic surgical aspirator (CUSA, Valleylab Boulder, CO, USA)
device and specimens for histopathologic diagnosis were obtained from the central parts of the
tumor. No carmustine wafers were introduced into the resection cavity.
All patients underwent pre- and post-operative [18F]FET-PET and MRI. Intra-operative
assessment of tumor resection with 5-ALA-induced fluorescence and clinical follow-up
(including imaging) served as additional reference standards. The study was approved by the
local ethics committee of Technical University, Munich, Germany. Written informed consent
was obtained from all patients.
Imaging protocols
The PET studies were performed prior to and after (mean, 3±2 days; median, 2 days) the resec-
tion using a dedicated ECAT EXACT HR+ PET scanner (Siemens CTI, Knoxville, TN, USA)
in 3-D mode. 182±34 MBq of [18F]FET were intravenously injected. Patients were positioned
supine using a low-attenuation head holder. Static acquisitions from 20–40 min p.i. followed
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by a 7 minute transmission scan using [68Ga]/[68Ge] rod sources were performed. Images were
reconstructed using 3D filtered backprojection with a Hann filter (cut off frequency 0.34) and
corrected for attenuation, scatter and randoms.
MRI was performed on a Philips Achieva 3.0 MR-tomograph (Philips Healthcare, Amster-
dam, The Netherlands). Patients were positioned supine. Pre-operatively, axial T1±Gd, T2
FLAIR, T2, DWI with ADCmap and 3D T1+Gd for navigation sequences were acquired.
After resection (mean; 1±1 day; median; 1 day), axial T1±Gd and subtraction, T2 FLAIR
and T2 sequences were obtained. Follow-up MRI and/or PET scans were performed at inter-
vals of three months or at clinical suspicion of tumor recurrence/progression.
Data analysis
PET:
Pre-operative scans served as reference for post-operative imaging. Analysis was performed
by visual comparison (B.K., C.L.) of both data sets. Focal [18F]FET uptake in the primary
tumor region higher than background was considered positive for tumor tissue.
MRI:
All images were analyzed independently by an experienced neuroradiologist who was
blinded to the PET data. Residual tumor was defined as previously described [18].
Histopathology and Immunohistochemistry
All tumor samples were histologically assessed and graded using standard hematoxylin and
eosin (H&E) sections (3–4 μm) according to the 2007 World Health Organisation criteria [19].
The astrocytic origin of the tumors was confirmed by positive immunoreaction for the glial
fibrillary acidic protein (GFAP 1:200, Dako, Glostrup, Denmark). Oligodendroglial features
were assured by the distinct pattern of microtubule-associated protein 2 immunoreactivity
(MAP2 1:250, Dako, Glostrup, Denmark).
Results
Tumor characteristics
All patients showed contrast-enhancing brain tumors in pre-operative MRI. Histopathology
confirmed HGG in 21/25 patients: 18/25 had glioblastoma, 3 patients anaplastic oligoastrocy-
toma. 2 patients suffered from grade II oligodendroglioma, the remaining 2 from grade II
astrocytoma. Information on the patients´ characteristics is provided in Table 1.
[18F]FET-PET imaging results in comparison to the reference standards
Intra-surgical assessment of resection status using 5-ALA postulated complete resection in 17/
25 [76%) of cases. Post-operative MRI was concordantly negative for remaining tumor in 17/
25 subjects. In one patient, it was negative despite intra-operative concern for incomplete
resection, in another case it detected contrast enhancement highly suspicious for vital tumor in
contrast to a negative surgical report. In 12/25 patients (48%) post-operative [18F]FET-PET
revealed no remaining tumor tissue consistent with the two other reference modalities. An
example is given in Fig 1. In the remaining 13 subjects (52%), focally increased [18F]FET uptake
suspicious for tumor remnants was observed. 6 out of those 13 cases (46%) were consistent
with both MRI and 5-ALA and therefore considered true positive.
In 7 patients, PET revealed discordant findings. In one subject (#15), both PET and 5-ALA
were positive for residual tumor whereas MRI did not indicate tumor tissue. This patient died
only three months after brain surgery. In another patient (#23), both imaging modalities raised
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Table 1. Patients´ characteristics.
Patient Age (in years) Gender Histopathology
1 58 Male Glioblastoma
2 37 Female Anaplastic oligoastrocytoma III
3 60 Male Glioblastoma
4 76 Female Oligodendroglioma II
5 64 Male Glioblastoma
6 69 Male Glioblastoma
7 63 Male Glioblastoma
8 41 Male Astrocytoma II
9 70 Female Glioblastoma
10 68 Male Glioblastoma
11 64 Male Glioblastoma
12 23 Male Astrocytoma II
13 52 Male Anaplastic oligoastrocytoma III
14 56 Male Glioblastoma
15 75 Male Glioblastoma
16 73 Male Glioblastoma
17 56 Male Glioblastoma
18 65 Male Glioblastoma
19 52 Female Oligodendroglioma II
20 63 Female Glioblastoma
21 79 Female Glioblastoma
22 46 Female Glioblastoma
23 69 Female Glioblastoma
24 37 Female Anaplastic oligoastrocytoma III
25 57 Male Glioblastoma
doi:10.1371/journal.pone.0141153.t001
Fig 1. Example of a complete resection. Patient #2. Transaxial slices. A: Intense focal [18F]FET uptake in the right temporal lobe. B:MRI (FLAIR-
sequence) with diffuse hyperintensity in the same region. C: [18F]FET-PET (48h after resection) andD:MRI (24 h after resection, FLAIR) with no signs of
residual tumor tissue.
doi:10.1371/journal.pone.0141153.g001
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the concern for viable tumor despite negative intra-surgical assessment. This patient deceased
five months later. In the remaining 5 patients (#7, 16, 18, 21, 22), PET was the only modality to
demonstrate tumor remnants. One patient (#7) was suitable for re-resection which was per-
formed 48 h after the first surgery. Histopathology confirmed vital tumor tissue exactly at the
spot of maximum [18F]FET-PET uptake (Fig 2). All other lesions detected by [18F]FET-PET
could not be re-resected due to tumor localization and were followed-up. After three months,
recurrence exactly at the site of initial tracer accumulation in post-operative PET was detected
in three of the five patients (#16, 18, 22; Fig 3). All patients underwent radiation therapy. The
remaining patient (#21) died three months after surgery. Table 2 gives an overview over the
imaging results of the individual patients.
Fig 2. Residual glioma tissue detected by [18F]FET-PET–Re-resection. Patient #7. Transaxial slices of [18F]FET-PET (upper row) and corresponding
contrast-enhanced T1-weighted MRI. A: Pre-operative PET with intense focal uptake in the left frontal lobe consistent with a lesion on MRI. B: Early
postoperative PET with focal uptake at the cranio-medial border of the resection cavity, leading to re-resection; MRI displaying unspecific changes. C: Early
postoperative PET after re-resection showing the resection cavity with no focal uptake in the border region, consistent with complete resection (confirmed by
MRI). Histopathology confirmed glioblastoma.
doi:10.1371/journal.pone.0141153.g002
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Fig 3. Residual tumor tissue detected by [18F]FET-PET—Follow-up. Patient #18.A,B: sagittal slices.C,D: axial slices.A: Pre-operative PET showing
focal uptake in the right parietal lobe. B: Suspicious uptake in the cranial border of the resection cavity 48h andC: 4 months after resection, consistent with
vital tumor.D: Corresponding MRI 4 months after resection corroborating the PET finding.
doi:10.1371/journal.pone.0141153.g003
Table 2. Comparison of all 3 modalities: PET, MRI and intraoperative findings (IF).
Patient Resection status Miscellaneous
IF MRI PET
1 IR IR IR -
2 CR CR CR -
3 CR CR CR -
4 CR CR CR -
5 CR CR CR -
6 CR CR CR -
7 CR CR IR Re-resection
8 CR CR CR -
9 IR IR IR -
10 CR CR CR -
11 IR IR IR -
12 CR CR CR -
13 CR CR CR -
14 IR IR IR -
15 IR CR IR Death after 3 months
16 CR CR IR Recurrence at PET site
17 IR IR IR -
18 CR CR IR Recurrence at PET site
19 CR CR CR -
20 CR CR CR -
21 CR CR IR Death after 3 months
22 CR CR IR Recurrence at PET site
23 CR IR IR Death after 5 months
24 CR CR CR -
25 IR IR IR -
IR = incomplete resection; CR = complete resection.
doi:10.1371/journal.pone.0141153.t002
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Discussion
The aim of this pilot study was to assess the value of early post-operative [18F]FET-PET in the
detection of residual tumor tissue in HGG patients. PET results were compared to MRI, intra-
operative reports and histopathology.
While various studies have demonstrated the value of amino-acid based PET with both
[11C]-methionine and [18F]FET in brain tumors including the detection of primary [14, 20–22]
and recurrent disease [15, 23], the differentiation between radiation necrosis versus tumor
recurrence [24], as well as therapy monitoring (16), this is the first study to investigate the per-
formance of early post-operative [18F]FET-PET.
Our data suggest that PET can detect vital residual tumor tissue with high accuracy. All
patients with complete resection were correctly classified by PET, thus proving a high negative
predictive value. Interestingly, the rate of complete resections of this series was quite high with
75%, but might be explained by the multi-modality approach prior to surgery as well as benefi-
cial localization of the individual tumors in many cases allowing for unlimited surgical
approaches.
Compared to MRI, early post-operative [18F]FET-PET showed a comparable accuracy in
the evaluation of the resection status. In 19/25, both imaging modalities were in concordance
indicating complete (n = 12) and incomplete (n = 7) resection. One patient with glioblastoma
in whom both [18F]FET-PET and MRI detected vital tumor tissue in discordance to negative
intra-operative assessment died only five months after imaging.
Additionally, [18F]FET-PET was more sensitive than MRI in 24% (6/25) of cases in which
MRI was false negative as proven by histopathology or short-term follow-up. It impacted on
patient management in one subject who successfully underwent surgical re-evaluation. These
results are in line with a previously published study that referred the possibility of early post-
operative PET-imaging with [11C]-methionine in glioma patients. Tanaka et al. could demon-
strate the feasibility of a multimodal navigation system using metabolic ([11C]-methionine-
PET) and anatomical (MRI) information in glioma patients and reported on tumor remnants
exclusively detected by post-operative PET in 2 of 12 cases [25]. Our data add evidence on the
suitability of early metabolic imaging after glioma surgery.
There are limitations of this study. First, image guided tissue sampling would have been nec-
essary to validate whether remnants (either in MRI or PET) were truly tumor tissue, especially
for conflicting results in the two post-operative imaging modalities. Second, only a small num-
ber of patients were included in this pilot study. Third, the problem of brain shift occurring
after surgery cannot be completely excluded thereby complicating analysis of early post-opera-
tive imaging. Last, histological work-up did not take into account spatial information to corre-
late imaging findings with surgery.
To date, MRI is the gold standard of brain imaging. In a large study more than 200 patients
with newly diagnosed glioblastoma, subjects with residual contrast-enhancing tumor as
revealed by early MRI scans had a shorter median overall survival from the time of surgery as
compared to patients without residual tumor (1, 2). Detection of residual vital tumor is there-
fore critical. However, MRI is prone to unspecific changes which can occur early after surgery.
Additional PET imaging could raise confidence of diagnosis and impact on adjuvant therapy,
e.g. tailored radiotherapy, by guiding a potential boost to tumor areas. Furthermore, early
knowledge of the post-operative PET status can prove extremely useful in the setting of follow-
up imaging in which the differentiation of true tumor recurrence from pseudo-progression has
important therapeutic implications.
In conclusion, early assessment of the resection status in HGG seems to be feasible with
[18F]FET-PET and might prove helpful for the prediction of residual tumor tissue or early
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recurrence. Future studies are warranted to further evaluate the value of early post-surgical
[18F]FET-PET and its implications on patient management.
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